Reporting owner · CIK 0001992352

Guarini Kathryn

Visual SEC Form 4 history across 1 companies, 9 transactions and 4 filings.

DIRREGENERON PHARMACEUTICALS, INC.
Open-market mix
Latest filingSep 03, 2026, 08:47 PM
Filings4Form 4 records
Buying$00 purchases
Selling$340K1 sales
Net value−$340KBuys minus sells
Companies12 securities
Most recentSep 02, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-5Jan 24Jan 25Jan 261Sep 26

Net value flow

Buys minus sells

Jan 24
$0
Jan 25
$0
Jan 26
$0
Sep 26
−$340K

Transaction texture

Ownership and ticket size

Average P/S size$340K
Median P/S size$340K
Direct9
Indirect0
Sep 02, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Derivative Transactionfiling-context3Direct Ownershipfiling-context6Large Holdings Increaseholdings5

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at REGENERON PHARMACEUTICALS, INC. on Sep 02, 2026 valued at $340,000.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at REGENERON PHARMACEUTICALS, INC. on Sep 02, 2026 valued at $340,000.

Review SEC filing

Associated companies

Visual map of known reporting history

REGNREGENERON PHARMACEUTICALS, INC.9 transactions · latest Sep 03, 2026, 08:47 PM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
REGNGuarini Kathryn
DIR
exercise10b5-1400$0M
Derivative Transaction Direct Ownership Large Holdings Reduction+1
0.0%09/0309/02
REGNGuarini Kathryn
DIR
sale10b5-1400-$34.0MS
Direct Ownership Large Holdings Reduction 10b5-1 Detected
0.0%09/0309/02
REGNGuarini Kathryn
DIR
exercise10b5-1400$28.7MM
Direct Ownership Large Holdings Increase 10b5-1 Detected
0.0%09/0309/02
REGNGuarini Kathryn
DIR
grant1.96k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
−1.7%01/0601/02
REGNGuarini Kathryn
DIR
grant155$0A
Direct Ownership Large Holdings Increase
−1.7%01/0601/02
REGNGuarini Kathryn
DIR
grant1.95k$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/06/202501/02/2025
REGNGuarini Kathryn
DIR
grant166$0A
Direct Ownership Large Holdings Increase
—01/06/202501/02/2025
REGNGuarini Kathryn
DIR
grant508$0A
Derivative Transaction Direct Ownership Large Holdings Increase
—01/04/202401/02/2024
REGNGuarini Kathryn
DIR
grant42$0A
Direct Ownership
—01/04/202401/02/2024

Guarini Kathryn Insider Activity FAQ

SEC Form 4 context

Who is Guarini Kathryn?

Guarini Kathryn is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001992352.

Which companies has Guarini Kathryn reported transactions for?

REGENERON PHARMACEUTICALS, INC.

When was Guarini Kathryn's latest insider buy?

No open-market insider purchase is available for this period.

When was Guarini Kathryn's latest insider sale?

sale at REGENERON PHARMACEUTICALS, INC. on Sep 02, 2026 valued at $340,000.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.